Novartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
News that Novartis is the latest pharma giant to exit the antibiotics space has prompted warnings that the ability to tackle antimicrobial resistance is getting weaker and could get worse if the failure of the antibiotic business model is not addressed.